In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia

Leukemia and Lymphoma

Volumn 28, Issue 1-2, 1997, Pages 103-112

  Cavazzana Calvo, M ^a   Jabado, N ^a   Bordigoni, P ^b   Michel, G ^c   Haddad, E ^a   Mechinaud, F ^d   Landman Parker, J ^e   Leblanc, T ^f   Plouvier, E ^g   Baruchel, A ^f   Stephan, J L ^h   Souillet, G ⁱ   Vilmer, E ^j   Wijdenes, J ^g   Le Deist, F ^a   Fischer, A ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c TIMONE HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Hôpital Diaclone   (France)

^h Hop Pediat de Saint Etienne   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

Adhesion molecules and monoclonal antibodies; Graft rejection; High risk ALL; Incompatible BMT

Indexed keywords

CD2 ANTIGEN; LYMPHOCYTE ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GRAFT FAILURE; HLA MATCHING; HUMAN; INFANT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

EID: 6844250973     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058336     Document Type: Article

References (50)

1. Barrett, J. A., Horowitz, M. M., Pollock, B. H., et al. (1994). Bone marrow transplants from HLA identical siblings as compared with chemiotherapy for children with acute lymphoblastic leukemia in a second remission. New Engi J. Med., 331, 1253-1258.
2. Kernan, N. A., Bartsch, G., Ash, R. C., et al. (1993). Analyse of 462 transplantations from unrelated donors facilitated by the national marrow donor program. New. Eng. J. Med, 328, 593-602.
3. Marmont, A. M., Horowitz, M. M. and Gale, R. P. (1991). T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120-2130.
4. Kernan, R., Flomenberg, N. and Dupont, B. (1987). Graft rejection in recipient of T-cell depleted HLA non identical marrow transplants for leukemia. Transplantation, 43, 842-848.
5. Ash, R. C., Casper, I. T., Chitambar, C. R., et al. (1990). Successful allogeneic transplantation of T-cell depleted unrelated donors, N. Engl. J. Med., 322, 485.
6. Van Seventer, G. A., Shimizu, Y., Horgan, K. J., et al. (1990). The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor-mediated activation of resting cells. J. Immunol., 144, 4579-4583.
7. Springer, T. A. (1990). Adhesion receptors of the immune system. Nature, 346, 425-434.
8. Hyners, R, O. (1992). Integrins: versatility, modulation and signaling in cell adhesion. Cell, 69, 11-25.
9. Fischer, A. (1991). Anti-LFA-1 antibody as immunosuppressive reagent in transplantation. Chem. Immunol., 50, 89-97.
10. Ybarrrondo, B., O'Rourke, A. M., Brian, A. A., et al. (1994). Contribution of lymphocyte-function associated-1/Intercellular adhesion molecule-1 binding to the adhesion/Signaling cascade of cytotoxic T-lymphocyte Activation. J. Exp. Med., 179, 359-363.
11. Fischer, A., Lisowska-Grospierre, B., Anderson, D. and Springer, T. (1988). The leukocyte adhesion deficiency. Immuno. Def. Rev., 2, 39-54.
12. Kohl, S., Loo, L. S., Schmalstieg, F. S., et al. (1986). The genetic deficiency of leukocyte surface glycoproteins Mac-1, LFA-1, p150 95 in humans is associated with defective antibody-dependent cellular cytotoxicity and defective protection against herpes simplex virus infection in vivo. J. Immunol., 171, 1688-1693.
13. Le Deist, F., Blanche, S., Keable, H., et al. (1989). Successful HLA non identical bone marrow transplantation in three patients with leukocyte adhesion deficiency. Blood, 74, 512-517.
14. Thomas, C., Le Deist, F., Cavazzana-Calvo, M., et al. (1995). Bone marrow transplantation for the treatment of the children with leucocyte adhesion deficiency. A revue of 14 cases. Blood, 86, 1629-1635.
15. Schwartz, R. H. (1989). Acquisition of immunologie self-tolerance. Cell, 57, 1073-1076.
16. Isobe, M., Yagita, M., Okumuro, K., et al. (1992). Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science, 255, 1125-1127.
17. Van Dijken, P. J., Ghayur, T., Mauch, P., et al. (1990). Evidence that anti LFA-1 in vivo improves engraftment and survival after allogenic bone marrow transplantation. Transplantation, 40, 882-886.
18. Cavazzana-Calvo, M., Sarnacki, S., Haddad, E., et al. (1995). Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Transplantation, 59, 1576-1582.
19. Nakakura, E. K., Mc Cabe, S. M., Zheng, G., et al. (1993). Potent and effective prolongation by anti-LFA-1 monoclonal antibody therapy of non primarily vascularized heart allograft survival in mice without T-cell depletion. Transplantation, 55, 412-417.
20. Kameoka, M., Ishibashi, M., Tamantani, T., et al. (1993). The immuno suppressive action of anti-CD 18 monoclonal antibody in rat heterotopic heart allotransplantation. Transplantation, 55, 665-667.
21. Gotoh, M., Fukuzaki, T., Monden, M., et al. (1994). A Potential immunosuppressive effect of antilymphocyte function associated antigen 1- monoclonal antibody on islet transplantation. Transplantation, 57, 123-126.
22. Fischer, A., Friedrich, W., Blanche, S., et al. (1991). Reduction of graft failure by a monoclonal antibody (anti LLFA-1CD11a) after HLA non identical bone marrow transplantation in children with inborn errors. Blood, 2, 249-256.
23. Perez, N., Le Deist, F., Chatenoud, L., et al. (1989). In vivo infusion of anti-LFA-1 antibody in HLA non identical bone marrow transplantation in children: Serum concentrations and biological effects. Bone Marrow Transplant, 4, 379-389.
24. Bierer, B. E., Burakof, S. J. (1989). T-lymphocyte activation: the biology and function of CD2 and CD4. Immunol Rev., 111, 267-294.
25. Hahn, W. C., Menu, E., Bothwell, A. L., Sims, P. J. and Bierer, B. E. (1992). Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science, 256, 1805-1807.
26. Kato, K., Koyanagi, M., Okada, H., et al (1992). CD48 is a counter-receptor for mouse CD2 and is involved in T-cell activation. J. Exp. Med., 176, 1241-1249.
27. Qin, L., Chavin, K. D., Lin, J., et al. (1949). Anti-CD 2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J. Exp. Med., 179, 341-346.
28. Miller, G. T., Hochman, P., Meier, W., et al. (1993). Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T-cell responses. J. Exp. Med., 178, 211-222.
29. + T-cells. Eur J Immunol., 25, 2285-2294.
30. Jabado, N., Le Deist, F., Cant, A., et al. (1996). Bone marrow transplantation from genetically HLA-non identical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics, 98, 420-428.
31. Baume, D., Kuentz, M., Pico, J. L., et al. (1989). Failure of a CD 18/anti-LFA-1 monoclonal antibody infusion to prevent graft rejection in leukemic patients receiving T-depleted allogenic bone marrow transplantation. Transplantation, 48, 472-474.
32. Cavazzana-Calvo, M., Bordigoni, P., Michel, G., et al. (1996). A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children. Prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Brit J Haematol., 93, 131-138.
33. Hale, G., Bright, S., Chumbley, et al. (1983). Removal of T-cells from bone marrow transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement. Blood, 62, 873-882.
34. Socie, G., Landmann, J., Gluckmann, E., et al. (1992). Short term study of chimaerism after bone marrow transplantation for severe aplastiec anaemia. British. J. of Heamatol., 80, 391-398.
35. Glucksberg, H., Storb, R. and Fefer, A. (1994). Clinical manifestations of GVHD in human recipients of marrow from HLA mached sibling donors. Transplantation, 18, 295-301.
36. Nakakaoni, Y., Mitani, K., Yamada, M., et al. (1986). A human chromosome specific repreated DNA family (DY21) consists of a tandem assay of pentanucleotides. Nucleic Acids Research, 14, 7569-7574.
37. Stephan, J. L., Vlekava, V., Le Deist, F., et al. (1993). Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatr., 123, 564-572.
38. Henze, G., Fengler, R., Hartmann, R., et al. (1991). Six-years experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukaemia (ALL-REZ-BFM 1985); a relapse study of the BFM group. Blood, 78, 1166-1172.
39. Borgmann, A., Schmid, G., Hartmann, R., et al. (1995). Autologous bone marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-fair analysis. The Lancet, 346, 873-876.
40. Beyerumann, B., Agthe, A. G., Adams, H. P., et al. (1996). Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukaemia expressing BCR-ABL fusion transcripts. Blood, 87, 1532-1538.
41. Janka-Schaub, G. E., Harms, D., Goebel, V., et al. (1996). Randomired comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood following after 9 years. Eur. J. Pediatr., 155, 640-648.
42. Schoch, C., Rieder, H., Freund, M., et al. (1995). Twentythree cases of acute lymphoblastic leukaemia with translocation + (4;11) (921;923): the implication of additional chromosomal aberrations. Ann. Hematol., 70, 195-201.
43. Hilden, J. M., Frestedt, J. L., Roderick, O. M., et al. (1995). Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase polymerase chain reaction for T (4;11) (921;923). Blood, 86, 3876-3882.
44. Cavazzana-Calvo, M., Jabado, N., Haddad, E., et al. (1996). Ex vivo B and T-lymphocyte depletion of partially incompatible marrow graft. Blood, 88, supplement 1, 420.
45. Oakhill, A., Pamphilon, D. M., Potten, M. N., et al. (1996). Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. British. J. Haematol., 94, 574-578.
46. Lapidot, T., Lubin, I., Aerenzi, A., Faktorowich, Y., et al. (1990). Enhancement of bone marrow allografts from nude mice into mismatched recipients by T-cells void of graft versus host activity. Proc. Natl. Acad. Sci. USA, 87, 4595.
47. Balduzzi, A., Gooley, T., Anasuti, C., et al. (1995). Unrelated donor marrow transplantation in children. Blood, 86, 3247-3256.
48. Rooney, C. M., Smith, C. A., et al. (1995). Use of gene-modified virus-specific T-lymphocytes to control Epstein Barr-Virus related lymphoproliferation. Lancet, 345, 9-13.
49. Tiberghien, P., Reynolds, C. W., Keller, J., et al. (1994). Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood, 84, 1333-1341.
50. Cavazzana-Calvo, M., Stephan, J. L., Sarnacki, S., et al. (1994). Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T-cells in an H-2 haplotype disparate mouse combination. Blood, 83, 288-293.